{"id":"davercin","rwe":[{"pmid":"19573386","year":"2009","title":"[Analysis of the infection status and the drug resistance of mycoplasma and chlamydiae in genitourinary tracts of children with suspected nongonococcal urethritis].","finding":"","journal":"Zhonghua er ke za zhi = Chinese journal of pediatrics","studyType":"Clinical Study"},{"pmid":"11284777","year":"2001","title":"Comparative efficacy of new investigational agents against Helicobacter pylori.","finding":"","journal":"Alimentary pharmacology & therapeutics","studyType":"Clinical Study"},{"pmid":"8348088","year":"1993","title":"[Drug sensitivity of bacillus strains M. avium-intracellulare (MAIC), M. kansasii cultured from patients with mycobacteriosis before treatment].","finding":"","journal":"Pneumonologia i alergologia polska","studyType":"Clinical Study"},{"pmid":"1492036","year":"1992","title":"[Urinary tract infection caused by Chlamydia trachomatis in children].","finding":"","journal":"Polski tygodnik lekarski (Warsaw, Poland : 1960)","studyType":"Clinical Study"},{"pmid":"2813147","year":"1989","title":"[Comparative studies of cyclic 11, 12 erythromycin carbonate (davercin) and erythromycin a levels in lung tissue, serum and bronchial secretions].","finding":"","journal":"Pneumonologia polska","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":["NCT04278404"],"aliases":[],"patents":[],"pricing":[],"allNames":"erythromycin a carbonate","offLabel":[],"synonyms":["erythromycin a carbonate","davercin","erythromycin A 11,12-carbonate","erythromycin A cyclic 11,12-carbonate","erythromycin cyclic carbonate"],"timeline":[],"approvals":[],"brandName":"Erythromycin A Carbonate","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like factories that make proteins. Bacteria are like tiny factories that also make proteins, but they can cause harm. Erythromycin A Carbonate stops these bacterial factories from making proteins, which ultimately kills the bacteria and treats the infection.","oneSentence":"Erythromycin A Carbonate works by inhibiting bacterial protein synthesis.","technicalDetail":"Erythromycin A Carbonate is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting the translocation step of protein synthesis and ultimately leading to bacterial cell death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3940","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=davercin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:25:55.962031","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"davercin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04278404","phase":"N/A","title":"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs","status":"RECRUITING","sponsor":"Duke University","isPivotal":false,"enrollment":5000,"indication":"Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension","completionDate":"2027-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"4H3125L82R","CHEBI":"CHEBI:135881","UMLSCUI":"C0112405","PUBCHEM_CID":"10033072","MESH_SUPPLEMENTAL_RECORD_UI":"C029784"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":14,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2009 Jan","pmid":"19573386","title":"[Analysis of the infection status and the drug resistance of mycoplasma and chlamydiae in genitourinary tracts of children with suspected nongonococcal urethritis].","journal":"Zhonghua er ke za zhi = Chinese journal of pediatrics"},{"date":"2001 Apr","pmid":"11284777","title":"Comparative efficacy of new investigational agents against Helicobacter pylori.","journal":"Alimentary pharmacology & therapeutics"},{"date":"1993","pmid":"8348088","title":"[Drug sensitivity of bacillus strains M. avium-intracellulare (MAIC), M. kansasii cultured from patients with mycobacteriosis before treatment].","journal":"Pneumonologia i alergologia polska"},{"date":"1992 Aug 7-17","pmid":"1492036","title":"[Urinary tract infection caused by Chlamydia trachomatis in children].","journal":"Polski tygodnik lekarski (Warsaw, Poland : 1960)"},{"date":"1989 Jan","pmid":"2813147","title":"[Comparative studies of cyclic 11, 12 erythromycin carbonate (davercin) and erythromycin a levels in lung tissue, serum and bronchial secretions].","journal":"Pneumonologia polska"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Erythromycin A Carbonate, also known as Davercin, is a small molecule antibiotic. It is used to treat various bacterial infections, although its specific indications are not provided. The commercial status of Davercin is unknown, and it may be patented or generic. Key safety considerations include potential gastrointestinal side effects and interactions with other medications. Further information on its pharmacokinetics and safety profile is needed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}